MX2019005141A - Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies. - Google Patents

Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies.

Info

Publication number
MX2019005141A
MX2019005141A MX2019005141A MX2019005141A MX2019005141A MX 2019005141 A MX2019005141 A MX 2019005141A MX 2019005141 A MX2019005141 A MX 2019005141A MX 2019005141 A MX2019005141 A MX 2019005141A MX 2019005141 A MX2019005141 A MX 2019005141A
Authority
MX
Mexico
Prior art keywords
dmpg
dmpc
lysopg
protective effect
channelopathies
Prior art date
Application number
MX2019005141A
Other languages
Spanish (es)
Inventor
Helson Lawrence
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/347,381 external-priority patent/US10117881B2/en
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of MX2019005141A publication Critical patent/MX2019005141A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Abstract

The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidylglycerol adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug.
MX2019005141A 2016-11-09 2017-11-09 Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies. MX2019005141A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/347,381 US10117881B2 (en) 2011-06-03 2016-11-09 Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
PCT/US2017/060936 WO2018089687A1 (en) 2016-11-09 2017-11-09 Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies

Publications (1)

Publication Number Publication Date
MX2019005141A true MX2019005141A (en) 2019-09-26

Family

ID=62109333

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005141A MX2019005141A (en) 2016-11-09 2017-11-09 Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies.

Country Status (8)

Country Link
EP (1) EP3538106A4 (en)
JP (1) JP2019533692A (en)
KR (3) KR20230110823A (en)
CN (1) CN110167562A (en)
AU (1) AU2017357916B2 (en)
CA (1) CA3042459C (en)
MX (1) MX2019005141A (en)
WO (1) WO2018089687A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7300394B2 (en) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
JP2020520380A (en) * 2017-05-16 2020-07-09 ボウ リバー エルエルシー Remedy
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
JP2024039728A (en) * 2022-09-12 2024-03-25 賢一郎 蓮見 Antitumor immune response enhancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812312A (en) * 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
JPH10279487A (en) * 1997-04-01 1998-10-20 Nippon Shokuhin Kako Co Ltd Lipid metabolism improver
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
US9447027B2 (en) * 2010-10-22 2016-09-20 The General Hospital Corporation Treating long QT syndrome
US8753674B2 (en) * 2011-06-03 2014-06-17 Signpath Pharma Inc. Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
US10117881B2 (en) * 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
CA2933204C (en) * 2013-12-18 2020-04-28 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
EP3151837B1 (en) * 2014-06-03 2023-03-15 Signpath Pharma, Inc. Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies

Also Published As

Publication number Publication date
AU2017357916B2 (en) 2020-11-26
EP3538106A1 (en) 2019-09-18
EP3538106A4 (en) 2021-03-24
CA3042459A1 (en) 2018-05-17
AU2017357916A1 (en) 2019-05-30
KR20230110823A (en) 2023-07-25
CA3042459C (en) 2022-08-16
KR20200108371A (en) 2020-09-17
WO2018089687A1 (en) 2018-05-17
JP2019533692A (en) 2019-11-21
KR20190067918A (en) 2019-06-17
CN110167562A (en) 2019-08-23

Similar Documents

Publication Publication Date Title
MX2019005141A (en) Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies.
EP3207931A3 (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
JOP20190281A1 (en) N2,n4-diphenylpyrimidin-2,4-diamine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
MX2016000364A (en) Methods for treating or preventing ophthalmological conditions.
MX2018003893A (en) Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough.
PH12016500356A1 (en) Nsaid and sigma receptor ligand combinations
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
PH12016501095A1 (en) Gabapentinoids and sigma receptor ligands combinations
BR112017028468A2 (en) solid oral formulation, and method for preparing a solid oral formulation
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2019001467A (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer.
CO2017003263A2 (en) Pharmaceutical composition based on anamorelin having activity on cachexia caused by cancer
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
MX2019004222A (en) Protective effect of dmpc, dmpg, dmpc/dmpg, egpg, lysopg and lysopc against drugs that cause channelopathies.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2023007136A (en) Protective effect of dmpc, dmpg, dmpc/dmpg, lysopg and lysopc against drugs that cause channelopathies.
MX2023006235A (en) Compositions for drug delivery and methods of use thereof.
RU2014107146A (en) METHOD FOR PREVENTING A CARCINOGENIC EFFECT OF DIETHYLNITROSAMINE IN EXPERIMENTAL ANIMALS
ZA202104167B (en) Compounds for use in the treatment of parkinson's disease
MX2016002509A (en) Pharmaceutical composition for the combination of desloratadine with montelukast for oral administration via pharmaceutical tablet or granular for the treatment of respiratory diseases.
UA91282U (en) Drug formulation possessing pronounced antigestagenic activity